Efficacy of Supplemental MRI for Breast Cancer Screening in Extremely Dense Tissue

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Annals of Internal Medicine https://doi.org/10.7326/ANNALS-26-00214 
Dr. Elena B. Elkin  et al.

Points

Researchers evaluated the clinical impact of adding supplemental MRI to digital breast tomosynthesis for women with extremely dense breasts across various levels of breast cancer risk.
The study found that supplemental MRI averted up to zero point eight additional deaths per one thousand women but also generated up to one hundred eighty-six additional false-positive biopsies.
Supplemental imaging directed at women with at least twice the average cancer risk provided reasonable economic value with incremental cost-effectiveness ratios remaining below one hundred thousand dollars.
Biennial MRI starting at age fifty was more effective than standard digital breast tomosynthesis beginning at age forty-five for all investigated risk groups within the simulation.
Findings suggest that clinicians should prioritize supplemental MRI for high-risk patients while working to reduce the high rates of false-positive recommendations that currently complicate the screening process.

Summary

This research evaluated the clinical impact and cost-effectiveness of supplemental breast MRI following digital breast tomosynthesis (DBT) in women aged 40 and older with extremely dense breasts. Given that federal law now requires breast density notification for over 40% of the 40 million women screened annually, investigators used simulation modeling to compare outcomes across varying relative risk (RR) levels. The study assessed how supplemental MRI affects breast cancer mortality and biopsy rates compared to DBT alone, particularly as breast density can significantly reduce the sensitivity of standard mammographic screening.

The data indicated that DBT alone averted 7.4 to 10.5 deaths per 1,000 average-risk women and 23.2 to 33.6 deaths in those with a four-fold higher RR. For the subset with extremely dense breasts, adding supplemental MRI (DBT + MRId) averted an additional 0.1 to 0.8 deaths but resulted in 22 to 186 additional false-positive biopsy recommendations. For women with an RR ≥2, biennial supplemental MRI showed comparable false-positive biopsy rates per death averted to those of DBT in average-risk populations, though starting MRI at age 50 was generally more effective than starting DBT at age 45 across all risk groups.

Economic analysis revealed that the value of supplemental MRI is highly contingent upon cancer risk and procedural costs. Incremental cost-effectiveness ratios (ICERs) suggested that MRI directed to higher-risk women (RR ≥2) with dense breasts provides reasonable value (ICER <$100,000) only if MRI costs and false-positive rates are significantly reduced. Sensitivity analyses confirmed that while supplemental MRI enhances cancer detection and mortality reduction in high-risk cohorts, pre-screening risk assessment is critical to balance the clinical benefit against the increased burden of false-positive biopsies.

Link to the article: https://www.acpjournals.org/doi/10.7326/ANNALS-26-00214

References

Elkin, E. B., & McGuinness, J. E. (2026). Supplemental magnetic resonance imaging in breast cancer screening: The challenge of using wisely. Annals of Internal Medicine, ANNALS-26-00214. https://doi.org/10.7326/ANNALS-26-00214